Antiplatelet medications play an important role in the therapeutic strategies of coronary atherosclerotic heart disease. Tirofiban, a kind of thrombocyte glycoprotein Ⅱb/Ⅲa inhibitor, is extensively used in acute coronary syndrome and percutaneous coronary intervention to inhibit thrombocyte activation, prevent thrombosis and reduce the ischemic complications. Thrombocytopenia is well-known as common complication of glycoprotein Ⅱb/Ⅲa inhibitor. Most of time, tirofiban-induced thrombocytopenia is harmless to the patients’life, but sometimes it occurs to severe complications such as diffused alveolar hemorrhage. This article presents a tirofiban-induced thrombocytopenia case which is developed after percutaneous coronary intervention, and then reviews the diagnosis and treatment of tirofiban-induced thrombocytopenia and summarizes the differential diagnosis from other medications.